Betashell Eye Drops contain Betaxolol 0.5% w/v, a selective beta-blocker used for reducing elevated intraocular pressure in patients with glaucoma and ocular hypertension. Its precise formulation ensures safe and effective long-term ophthalmic management.
The eye drop works by decreasing aqueous humor production, helping to control eye pressure and prevent optic nerve damage, while maintaining good patient tolerance during prolonged therapy.
From a business perspective, Betashell Eye Drops are a high-demand anti-glaucoma ophthalmic product, commonly prescribed in eye hospitals, specialty clinics, and ophthalmology centers, ensuring consistent sales and repeat prescriptions.
Adding Betashell Eye Drops to your portfolio strengthens the ophthalmic anti-glaucoma segment, offering long-term market stability, strong prescriber confidence, and enhanced portfolio credibility for pharma franchise partners.